52: Alzheimer's Update--Expensive New Med vs Fasting & Keto (KetoFlex 12-3)
Description
Lecanemab (aka Leqembi) recently got full approval form the FDA for Alzheimer’s treatment, and will now be covered by Medicare. But this medication is not only expensive, it has some major health risks. In this episode, I'll break down the risks and benefits of this new medication. Then I’ll compare lecanemab to an Alzheimer's program centered around fasting and ketosis (along with a few other medical tests and treatments), developed by Dr. Dale Bredesen, author of “The End of Alzheimer’s”.
YouTube version: https://youtu.be/JpWBxxZqiwA
---Previous episode on Alzheimer’s prevention---
Video: https://youtu.be/Z2OVf_rmwOE
Podcast: https://fastingwell.com/episode22/
Blog: https://fastingwell.com/ketoflex-fasting-alzheimers/
---Dr. Bredesen's Books---
📙 The End of Alzheimer's: https://amzn.to/3DMwhmS
📘 The End of Alzheimer's Program: https://amzn.to/3NLlIVL
📗 The First Survivors of Alzheimer’s: https://amzn.to/3NNaBvj
Listen w/ a 30-day free trial on Audible: https://amzn.to/3gKo9vI
Full show notes and resources: https://fastingwell.com/episode52/
United States
